Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 15,000 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Yvonne Greenstreet also recently made the following trade(s):

• On Thursday, August 1st, Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00.
• On Thursday, July 11th, Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00.
• On Tuesday, June 25th, Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $1.84 during mid-day trading on Thursday, hitting $277.33. 528,608 shares of the stock traded hands, compared to its average volume of 884,624. The stock has a market cap of $35.08 billion, a P/E ratio of -104.17 and a beta of 0.37. The stock’s fifty day moving average is $239.54 and its two-hundred day moving average is $182.46. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $285.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.21) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after buying an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the period. Capital International Investors grew its stake in Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after acquiring an additional 64,560 shares during the period. Capital Research Global Investors grew its stake in Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after acquiring an additional 214,908 shares during the period. Finally, Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $390,438,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on ALNY shares. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the stock a “neutral” rating in a report on Wednesday, July 3rd. Finally, StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $277.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.